Live
CellA convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapyFierceBiotechAstraZeneca’s Strensiq successor misses phase 3 rare disease goal, denting market expansion planFierceBiotechLipella files for bankruptcy, ending dream of developing mouth inflammation drugBioPharma DiveMerck strikes deal with antibody discovery startupPharmaVoicemRNA is poised to rise beyond infectious diseases, if it’s not derailed by R&D cutsPharmaVoiceBig Pharma goes nuts over food allergies — againEndpoints NewsNovo Nordisk launches subscription program for Wegovy drugsEndpoints NewsBiogen to acquire Apellis for $5.6BEndpoints NewsPepGen’s muscle disease program posts poor mid-stage results as one patient's data get markedly worseEndpoints NewsViiV R&D head Kimberly Smith heads to retirement after three decades in HIV care10x Genomics BlogWhy 10x Genomics Stock Is Surging Higher Today - TipRanksEndpoints NewsEli Lilly to buy Centessa for $6.3B to get sleep disorder drug
Endpoints News Mar 31, 2026

PepGen’s muscle disease program posts poor mid-stage results as one patient's data get markedly worse

PepGen’s muscle disease program posts poor mid-stage results as one patient's data get markedly worse

Original
Body unavailable. Use the original source.

Directory

59 All